Neuroimmunology Drugs Market, By Product Type, By Indications, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Description

Neuroimmunology Drugs Market size was valued at US$ 25,815.10 Million in 2024, expanding at a CAGR of 9.90% from 2025 to 2032.

Neuroimmunology drugs are primarily used to treat neurological and immune system disorders. This includes neurological conditions such as neuromyelitis optica (NMO), multiple sclerosis (MS), and other autoimmune diseases. Many neurological disorders in this area are classified as autoimmune illnesses, which occur when the immune system misidentifies and attacks nervous system components, such as the myelin sheath in multiple sclerosis (MS).

Neuroimmunology Drugs Market- Market Dynamics

Increasing incidence of neuroimmunological disorders

The increasing prevalence of neuroimmunological disorders is driving market growth in the neuroimmunology drugs sector. As diagnoses rises the demand for effective treatments, resulting in a larger patient pool who require medication. This increased demand encourages pharmaceutical companies to invest heavily in R&D, which drives innovation and the development of new drugs. The growing patient population necessitates a broader range of therapeutic options, prompting scientists to investigate novel strategies and advanced drug prospects. As a result, the increasing prevalence of these disorders is directly proportional to increased market size, as more patients seek and require neuroimmunology drugs, driving market growth.

Neuroimmunology Drugs Market- Key Insights

Our research analyst estimates that the global market will grow at a CAGR of approximately 9.90% between 2025 and 2032.

Monoclonal antibodies are expected to have the highest market share in 2025.

Multiple sclerosis is the leading indication segment in 2025.

Asia Pacific is projected to generate the most revenue in 2025.

Neuroimmunology Drugs Market- Segmentation Analysis:

The Global Neuroimmunology Drugs Market is segmented on the basis of Product Type, Indications, and Region.

The market is divided into six categories based on product type: Monoclonal Antibodies, Small Molecules, Lymphocytes, Recombinant Protein, Cytokines, and Other Product Types. Monoclonal antibodies are commonly used as disease-modifying treatments for neuroimmunological conditions such as multiple sclerosis (MS) and neuromyelitis optica (NMO), so the monoclonal antibody segment is expected to grow rapidly. These mAbs, which aim to reduce inflammation and suppress the inflammatory response, may be able to slow the course of the illness and prevent relapses. Inflammation is a major factor in many neuroimmunological illnesses, and monoclonal antibodies can help to relieve pain and prevent further nerve tissue damage. Certain mAbs prevent the autoimmune system from attacking nervous system elements such as the myelin sheath, thereby aiding in the prevention of neurological damage.

The market is divided into nine categories based on Indications: Multiple Sclerosis, Alzheimer's Disease, Myasthenia Gravis, Guillain-Barre Syndrome, Parkinson's Disease, Neuromyelitis Optica Spectrum Disorder, Amyotrophic Lateral Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, and Other Indications. Multiple sclerosis (MS) is one of the most common neurological disorders in the market for neuroimmunology medications, and the segment is expected to grow at the fastest CAGR during the forecast period. The immune system incorrectly attacks the protective myelin layer that envelops nerve fibers in the central nervous system (CNS) in multiple sclerosis (MS), an autoimmune disease. This illness causes a wide range of neurological symptoms. Furthermore, as a result of ongoing research, novel treatments are being developed and existing medications are being repurposed for the treatment of multiple sclerosis, with the goals of these cutting-edge treatments being better results and more treatment options.

Neuroimmunology Drugs Market- Geographical Insights

Asia Pacific is expected to have the largest market share during the forecast period, as neuroimmunological diseases such as multiple sclerosis, neuromyelitis optical, and other autoimmune nervous system illnesses have become more common in the Asia Pacific region. Each country and region has a unique precise prevalence as a result of improved treatment options, early detection, and increased awareness of neuroimmunological illnesses. Several regional governments are working to improve neuroimmunological disease management. This includes funding for research, expanding the healthcare infrastructure, and encouraging early detection and intervention.

North America is expected to have the highest CAGR over the forecast period, owing to the prevalence of clinical trials for neuroimmunology-related medications in the region. It's a desirable location for clinical research due to its strong healthcare system, research institutes, and diverse patient population. The United States Food and Drug Administration (FDA) and Health Canada are two regulatory bodies that ensure the safety and efficacy of neuroimmunology medications, establishing a well-defined regulatory framework for drug approval. In North America, many patients have health insurance, which can help to reduce out-of-pocket treatment costs and improve access to neuroimmunology medications.

Neuroimmunology Drugs Market- Competitive Landscape:

The neuroimmunology drugs market is competitive, with several key players vying for market share. Major pharmaceutical companies such as Biogen, Hoffmann-La Roche Ltd, T3D Therapeutics, and Novartis AG are leading the way, investing heavily in R&D to bring innovative treatments to market. These companies frequently have a diverse portfolio of drugs that target various neuroimmunological disorders. Smaller biotechnology companies and emerging players are also contributing to the market, with many focusing on specific therapeutic areas or novel drug development strategies. Factors driving competition include drug efficacy, safety profiles, pricing strategies, and the ability to obtain regulatory approvals and market access. Collaborations, partnerships, and acquisitions are common strategies in this volatile market, as companies seek to diversify their product portfolios and strengthen their market positions.

Recent Developments:

In June 2023, Roche announced that it had signed a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company owned by Roivant Sciences Ltd. and Pfizer Inc. Telavant's RVT-3101 will be developed, manufactured, and commercialised in the United States and Japan under the terms of the agreement.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROIMMUNOLOGY DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Biogen
Hoffmann-La Roche Ltd
T3D Therapeutics
Novartis AG
Johnson & Johnson
Celgene Corp
Merck KGaA
Eisai Co Ltd
Sanofi
Actelion Pharmaceuticals Ltd
ImmunoBrain Checkpoint
Lundbeck, Eli Lilly
AstraZeneca
UCB SA
AB Science S.A
AstronauTx, Genetech Inc
Inflammasome Therapeutics
TauRX Therapeutics Ltd
Others

GLOBAL NEUROIMMUNOLOGY DRUGS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

Monoclonal Antibodies
Small Molecules
Lymphocytes
Recombinant Protein
Cytokines
Other Product Types

GLOBAL NEUROIMMUNOLOGY DRUGS MARKET, BY INDICATIONS- MARKET ANALYSIS, 2019 - 2032

Multiple Sclerosis
Alzheimer's Disease
Myasthenia Gravis
Guillain-Barre Syndrome
Parkinson's Disease
Neuromyelitis Optica Spectrum Disorder
Amyotrophic Lateral Sclerosis
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Other Indications

GLOBAL NEUROIMMUNOLOGY DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV5605

1. Neuroimmunology Drugs Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Neuroimmunology Drugs Market Snippet by Product Type
- 2.1.2. Neuroimmunology Drugs Market Snippet by Indications
- 2.1.3. Neuroimmunology Drugs Market Snippet by Country
- 2.1.4. Neuroimmunology Drugs Market Snippet by Region
2.2. Competitive Insights

3. Neuroimmunology Drugs Key Market Trends

3.1. Neuroimmunology Drugs Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Neuroimmunology Drugs Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Neuroimmunology Drugs Market Opportunities
3.4. Neuroimmunology Drugs Market Future Trends

4. Neuroimmunology Drugs Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Neuroimmunology Drugs Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Neuroimmunology Drugs Market Landscape

6.1. Neuroimmunology Drugs Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Neuroimmunology Drugs Market - By Product Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
- 7.1.2. Monoclonal Antibodies
- 7.1.3. Small Molecules
- 7.1.4. Lymphocytes
- 7.1.5. Recombinant Protein
- 7.1.6. Cytokines
- 7.1.7. Other Product Types

8. Neuroimmunology Drugs Market - By Indications

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indications, 2024 & 2032 (%)
- 8.1.2. Multiple Sclerosis
- 8.1.3. Alzheimer's Disease
- 8.1.4. Myasthenia Gravis
- 8.1.5. Guillain-Barre Syndrome
- 8.1.6. Parkinson's Disease
- 8.1.7. Neuromyelitis Optica Spectrum Disorder
- 8.1.8. Amyotrophic Lateral Sclerosis
- 8.1.9. Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- 8.1.10. Other Indications

9. Neuroimmunology Drugs Market- By Geography

9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
9.2. North America
- 9.2.1. Overview
- 9.2.2. Neuroimmunology Drugs Key Manufacturers in North America
- 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 9.2.5. North America Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.2.6. U.S.
  - 9.2.6.1. Overview
  - 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.6.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.2.6.4. U.S. Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.2.7. Canada
  - 9.2.7.1. Overview
  - 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.7.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.2.7.4. Canada Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.3. Europe
- 9.3.1. Overview
- 9.3.2. Neuroimmunology Drugs Key Manufacturers in Europe
- 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 9.3.5. Europe Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.3.6. Germany
  - 9.3.6.1. Overview
  - 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.6.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.6.4. Germany Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.3.7. UK
  - 9.3.7.1. Overview
  - 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.7.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.7.4. UK Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.3.8. France
  - 9.3.8.1. Overview
  - 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.8.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.8.4. France Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.3.9. Italy
  - 9.3.9.1. Overview
  - 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.9.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.9.4. Italy Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.3.10. Spain
  - 9.3.10.1. Overview
  - 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.10.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.10.4. Spain Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.3.11. The Netherlands
  - 9.3.11.1. Overview
  - 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.11.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.11.4. The Netherlands Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.3.12. Sweden
  - 9.3.12.1. Overview
  - 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.12.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.12.4. Sweden Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.3.13. Russia
  - 9.3.13.1. Overview
  - 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.13.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.13.4. Russia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.3.14. Poland
  - 9.3.14.1. Overview
  - 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.14.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.14.4. Poland Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.3.15. Rest of Europe
  - 9.3.15.1. Overview
  - 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.3.15.4. Rest of the Europe Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.4. Asia Pacific (APAC)
- 9.4.1. Overview
- 9.4.2. Neuroimmunology Drugs Key Manufacturers in Asia Pacific
- 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 9.4.5. APAC Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.4.6. China
  - 9.4.6.1. Overview
  - 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.6.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.6.4. China Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.4.7. India
  - 9.4.7.1. Overview
  - 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.7.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.7.4. India Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.4.8. Japan
  - 9.4.8.1. Overview
  - 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.8.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.8.4. Japan Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.4.9. South Korea
  - 9.4.9.1. Overview
  - 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.9.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.9.4. South Korea Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.4.10. Australia
  - 9.4.10.1. Overview
  - 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.10.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.10.4. Australia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.4.11. Indonesia
  - 9.4.11.1. Overview
  - 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.11.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.11.4. Indonesia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.4.12. Thailand
  - 9.4.12.1. Overview
  - 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.12.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.12.4. Thailand Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.4.13. Philippines
  - 9.4.13.1. Overview
  - 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.13.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.13.4. Philippines Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.4.14. Rest of APAC
  - 9.4.14.1. Overview
  - 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.14.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.4.14.4. Rest of APAC Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.5. Latin America (LATAM)
- 9.5.1. Overview
- 9.5.2. Neuroimmunology Drugs Key Manufacturers in Latin America
- 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 9.5.5. LATAM Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.5.6. Brazil
  - 9.5.6.1. Overview
  - 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.6.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.5.6.4. Brazil Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.5.7. Mexico
  - 9.5.7.1. Overview
  - 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.7.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.5.7.4. Mexico Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.5.8. Argentina
  - 9.5.8.1. Overview
  - 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.8.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.5.8.4. Argentina Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.5.9. Colombia
  - 9.5.9.1. Overview
  - 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.9.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.5.9.4. Colombia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.5.10. Rest of LATAM
  - 9.5.10.1. Overview
  - 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.10.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.6. Middle East and Africa (MEA)
- 9.6.1. Overview
- 9.6.2. Neuroimmunology Drugs Key Manufacturers in Middle East and Africa
- 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 9.6.5. MEA Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.6.6. Saudi Arabia
  - 9.6.6.1. Overview
  - 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.6.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.6.7. UAE
  - 9.6.7.1. Overview
  - 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.7.3. UAE Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.7.4. UAE Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.6.8. Israel
  - 9.6.8.1. Overview
  - 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.8.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.8.4. Israel Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.6.9. Turkey
  - 9.6.9.1. Overview
  - 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.9.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.9.4. Turkey Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.6.10. Algeria
  - 9.6.10.1. Overview
  - 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.10.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.10.4. Algeria Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.6.11. Egypt
  - 9.6.11.1. Overview
  - 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.11.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.11.4. Egypt Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
- 9.6.12. Rest of MEA
  - 9.6.12.1. Overview
  - 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.12.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 9.6.12.4. Rest of MEA Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Neuroimmunology Drugs Industry

10.1. Competitive Benchmarking
- 10.1.1. Competitive Dashboard
- 10.1.2. Competitive Positioning
10.2. Company Profiles
- 10.2.1. Biogen
- 10.2.2. Hoffmann-La Roche Ltd
- 10.2.3. T3D Therapeutics
- 10.2.4. Novartis AG
- 10.2.5. Johnson & Johnson
- 10.2.6. Celgene Corp
- 10.2.7. Merck KGaA
- 10.2.8. Eisai Co Ltd
- 10.2.9. Sanofi
- 10.2.10. Actelion Pharmaceuticals Ltd
- 10.2.11. ImmunoBrain Checkpoint
- 10.2.12. Lundbeck, Eli Lilly
- 10.2.13. AstraZeneca
- 10.2.14. UCB SA
- 10.2.15. AB Science S.A
- 10.2.16. AstronauTx, Genetech Inc
- 10.2.17. Inflammasome Therapeutics
- 10.2.18. TauRX Therapeutics Ltd
- 10.2.19. Others

11. 360 Degree AnalystView

12. Appendix

12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us